Ketorolac, pills 10mg, 10pcs

Composition

1 tablet contains ketorolac trometamine-10 mg

Pharmacological action

Ketorolac has a pronounced analgesic effect, also has an anti-inflammatory and moderate antipyretic effect.

The mechanism of action is associated with non-selective inhibition of cyclooxygenase 1 and 2 enzyme activity, mainly. in peripheral tissues, which results in inhibition of prostaglandin biosynthesis-modulators of pain sensitivity, thermoregulation, and inflammation. Ketorolac is a racemic mixture of [ – ] S and [+] R enantiomers, and the analgesic effect is due to the [-] S form.

The drug does not affect opioid receptors, does not depress respiration, does not cause drug dependence, does not have a sedative and anxiolytic effect.

The strength of the analgesic effect is comparable to morphine, significantly superior to other NSAIDs.

After oral use, the onset of analgesic action is noted, respectively, after 1 hour, the maximum effect is achieved in 1-2 hours.

Indications

Moderate to severe pain syndrome:

• postoperative pain,
• joint pain from injuries with torn ligaments,
• dislocations,
• sprains; back and muscle pain.

Contraindications

• hypersensitivity (including to aspirin, etc. NSAIDs),
• nasal polyps,
• angioedema,
• bronchospasm,
• bronchial asthma,
• gastric and duodenal ulcers,
• impaired renal function,
• hypovolemia,
• dehydration,
• high risk of postoperative bleeding or incomplete stopping of bleeding,
• impaired hematopoiesis,
• brain hemorrhage,
• early childhood (up to 2 years).

Side effects

• nausea,
• abdominal pain,
• diarrhea,
• drowsiness,
• headache,
• anxiety,
• damage to the gastric and intestinal mucosa,
• pain at the injection site.

Interaction

Concomitant use of ketorolac with other NSAIDs may lead to the development of additive side effects; with pentoxifylline, anticoagulants (warfarin, heparin in low doses) – may increase the risk of bleeding; with ACE inhibitors – may increase the risk of developing impaired renal function; with probenecid – increase the concentration of ketorolac in plasma and its half – life; with lithium preparations – may decrease the renal clearance of lithium and increase its concentration in plasma; with furosemide-reducing its diuretic effect.

When using ketoralac, the need for opioid analgesics for pain relief is reduced.

How to take, course of use and dosage

IV, IV, children only in injections.

The dose is selected individually, taking into account the severity of the pain syndrome.

With intravenous use, a single dose is 10-30 mg, the interval between injections is 4-6 hours.

The maximum duration of application is 5 days.

Maximum doses:  with intravenous use-90 mg / day; for patients with a body weight of up to 50 kg, with impaired renal function, as well as for persons over 65 years of age – 60 mg/day.

Ketorolac is taken orally, once or repeatedly, depending on the severity of the pain syndrome.

A single dose is 10 mg, with repeated use it is recommended to take 10 mg up to 4 times a day, depending on the severity of pain; the maximum daily dose should not exceed 40 mg.

When taken orally, the duration of the course should not exceed 5 days.

Overdose

Symptoms (with a single dose): abdominal pain, nausea, vomiting, erosive and ulcerative lesions of the gastrointestinal tract, impaired renal function, metabolic acidosis.

Treatment: symptomatic (maintenance of vital body functions). Dialysis is ineffective.

Special instructions

It is used with caution in patients with impaired liver and kidney function, chronic heart failure, arterial hypertension, in patients with erosive and ulcerative lesions of the gastrointestinal tract and a history of bleeding from the gastrointestinal tract, a history of blood clotting disorders.

Caution should be exercised when using ketorolac in the postoperative period in cases where particularly careful hemostasis is required (including after prostate resection, tonsillectomy, cosmetic surgery), as well as in senile patients, since the half-life of ketorolac is prolonged, and plasma clearance may decrease. In this category of patients, it is recommended to use ketorolac in doses that are at the lower limit of the therapeutic range.

If symptoms of liver damage, skin rash, or eosinophilia occur, ketorolac should be discontinued. Ketorolac is not indicated for use in chronic pain syndrome.

Effects on the ability to drive motor vehicles and control mechanisms If drowsiness, dizziness, insomnia or depression occur during ketorolac treatment, special care should be taken when engaging in potentially dangerous activities that require increased attention and speed of psychomotor reactions.

Storage conditions

Store in a dark place at a temperature of 15 to 25 °C.

Keep out of the reach of children.

Shelf life

2 years

Active ingredient

Ketorolac

Conditions of release from pharmacies

By prescription

Dosage form

Tablets